Randomized, Crossover Safety and Pharmacokinetics Study of PT010

• ClinicalTrials.gov Identifier: NCT02197975
• Recruitment Status: Completed
• First Posted: July 23, 2014
• Last Update Posted: October 28, 2014
• Sponsor: Pearl Therapeutics, Inc.
• Information provided by (Responsible Party): Pearl Therapeutics, Inc.

Study Description

Brief Summary:

Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days.

Condition or disease	Intervention/treatment	Phase
COPD	Drug: PT010 Dose 1; Drug: PT010 Dose 2; Drug: Placebo MDI	Phase 1

Detailed Description:

This is a Phase I, single-center, randomized, double-blind, placebo-controlled, two period, ascending dose, cross-over study to assess safety and PK of two doses of PT010 in healthy adult subjects of Japanese descent. Safety and PK will be assessed following a single dose and during twice-daily (BID) chronic dosing for 7 days.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase I, Randomized, Double Blind, Placebo-Controlled, Two Period, Ascending Dose, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days
• Study Start Date: August 2014
• Actual Primary Completion Date: October 2014
• Actual Study Completion Date: October 2014

Arms and Interventions

Arm	Intervention/treatment
Experimental: PT010 Dose 1; PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.	Drug: PT010 Dose 1; PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
Experimental: PT010 Dose 2; PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.	Drug: PT010 Dose 2; PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
Placebo Comparator: Placebo MDI; Placebo MDI. Administered as 2 inhalations	Drug: Placebo MDI; Placebo MDI. Administered as 2 inhalations

Outcome Measures

Primary Outcome Measures :

1. The pharmacokinetic profile of PT010 [ Time Frame: 12 hours ]

   The pharmacokinetic profile of PT010 will be assessed at the first day (Day 1) and last dose (Day 8) in each Treatment Period based on:

   • maximum plasma concentration (Cmax)
   • area under the plasma concentration-time curve from 0 to 12 hours (AUC0 12)
   • area under the plasma concentration-time curve from 0 to the time of the last measureable plasma concentration (AUC0-t)
   • area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC0-∞) (only calculated for Day 1)
   • time to maximum plasma concentration (tmax)
   • apparent terminal elimination half-life (t½)
   • apparent total body clearance (CL/F)
   • apparent volume of distribution (Vd/F)
   • terminal elimination rate constant (λz)
   • accumulation ratio for Cmax (RAC [Cmax])
   • accumulation ratio for AUC0 12 (RAC [AUC0 12]) Other PK parameters may be calculated, as appropriate.

Secondary Outcome Measures :

1. Overall safety of PT010 [ Time Frame: 12 hours ]
   The safety associated with the use of PT010 will be assessed from physical examination findings, adverse event (AE) reporting, vital signs, clinical laboratory values, and findings from 12 lead electrocardiograms (ECGs).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Informed Consent Form (ICF) prior to any study related procedures
• Male and female subjects first generation Japanese subjects 18 to 55 years, inclusive
• Body weight ≥50 kg (110 lbs) at the Screening Visit and body mass index between 18.5 and 32 kg/m2, inclusive
• Good general health
• Medically acceptable contraception for women of child-bearing potential and males with female partners of childbearing potential
• Clinical labs within normal ranges or determined to be not clinically significant by the Investigator

Exclusion Criteria:

• Pregnancy, nursing female subjects, or subjects trying to conceive
• Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study
• History of ECG abnormalities
• Cancer not in complete remission for at least 5 years
• Clinically significant, symptomatic prostatic hypertrophy
• Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening
• Clinically significant bladder neck obstruction or urinary retention
• Inadequately treated glaucoma
• History of an allergic reaction or hypersensitivity to any drug or to any component of the formulations used in this study
• Subjects with pre-existing anemia and/or iron deficiency

Contacts and Locations

Locations

United States, Maryland

SNBL Clinical Pharmacology Center

Baltimore, Maryland, United States, 21201

Sponsors and Collaborators

Pearl Therapeutics, Inc.

Investigators

• Study Chair: Chadwick Orevillo; Pearl Therapeutics

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Huang Y, Assam PN, Feng C, Su R, Dorinsky P, Gillen M. Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Pulm Pharmacol Ther. 2020 Oct;64:101976. doi: 10.1016/j.pupt.2020.101976. Epub 2020 Nov 2.

• Responsible Party: Pearl Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT02197975
• Other Study ID Numbers: PT010003-00
• First Posted: July 23, 2014
• Last Update Posted: October 28, 2014
• Last Verified: October 2014

Keywords provided by Pearl Therapeutics, Inc.:

Healthy Volunteers